甲磺酸瑞波西汀 T6963

Product Introduction
Bioactivity


英文名: Reboxetine mesylate

描述: Reboxetine mesylate (FCE20124 mesylate) 是一种高效、选择性的，特异性的去甲肾上腺素再摄取抑制剂(NARI)，能够抑制去甲肾上腺素再摄取(Ki=8 nM)，可用于抑郁症的研究。

体外活性: Reboxetine dose-dependently and completely inhibits [3H]-dopamine uptake to the human norepinephrine transporters (hNET) with Ki value of 11 nM in Madin–Darby canine kidney (MDCK) cells. [1]

体内活性: Reboxetine dose-dependently and potently inhibits locus coeruleus neuronal firing in rats with ED50 of 191 μg/kg. Reboxetine inhibition of the locus coeruleus neurons is reversible by the α2 antagonist piperoxan (1.5 mg/kg, IV). Reboxetine dose-dependently reverses reserpine-induced blepharospasm and hypothermia in the mouse. Reboxetine is also found to antagonize clonidine-induced hypothermia dose-dependently in mice. Reboxetine reverses reserpine-induced blepharospasm and hypothermia in rats with ED50 of 10 mg/kg and 3 mg/kg (p.o.), respectively. [1] Reboxetine results in a significant reduction in the mean number of panic attacks and phobic symptoms in patients with DSM-III-R panic disorder. Reboxetine also results in improvement in Hamilton Rating Scale for Depression, Hopkins Symptom Checklist-90, and Sheehan Disability Scale scores. [2] Reboxetine is associated with a markedly lower relapse rate than placebo (22% vs. 56%) and a greater cumulative probability of a maintained response during long-term treatment in patients with recurrent DSM-III-R major depression. Reboxetine effectively prevents recurrence of depressive symptoms following episode resolution. [3] Acute systemic administration of Reboxetine (0.3 mg/kg-20 mg/kg) dose-dependently increases extracellular norepinephrine in the rat frontal cortex while having no effect on extracellular serotonin. Reboxetine (20 mg/kg) also increases extracellular dopamine in the rat frontal cortex. Chronic administration of Reboxetine for 14 days results in elevated basal concentrations of extracellular norepinephrine and dopamine and a greater net increase of extracellular norepinephrine and dopamine, but not serotonin in the rat frontal cortex. [4] Reboxetine dose dependently decreases nicotine self-administration by ~60%. Repeated administration of Reboxetine (5.6 mg/kg) decreases nicotine self-administration and sucrose-maintained responding across the 14 sessions. [5]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: H2O : 20.5 mg/mL (50 mM)
DMSO : 20.5 mg/mL (50 mM)


关键字: disorder | FCE20124 | Adrenergic Receptor | activity | FCE-20124 Mesylate | depression | antidepressant | Reboxetine mesylate | panic | Beta Receptor | FCE-20124 | FCE 20124 Mesylate | FCE 20124 | inhibit | PNU155950E | Reboxetine | PNU155950E Mesylate | FCE20124 Mesylate | Reboxetine Mesylate | Inhibitor

相关产品: Cisatracurium besylate | Midodrine hydrochloride | Quinine HCl | Dabuzalgron | Terazosin hydrochloride dihydrate | Carazolol | ACTH 1-14 acetate(25696-21-3 free base) | Ketanserin tartrate | Doxazosin mesylate | Naftopidil

相关库: Adrenergic Receptor-Targeted Compound Library | Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | GPCR Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | EMA Approved Drug Library

甲磺酸瑞波西汀 T6963信息由TargetMol中国为您提供，如您想了解更多关于甲磺酸瑞波西汀 T6963报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途